Advanced Liver Disease
The liver is at the center of everything we do
Chronic liver disease represents a global public health problem, with about 100 million people suffering from cirrhosis. The main causes are viral infections, alcohol and obesity, as well as, autoimmune and genetic diseases.4
Need for new treatments remains high
Need for new treatments remains high
844million
people suffering from chronic liver disease in the world1
2m+
deaths per year worldwide, a rising number1
TOP 5
cause of death in middle age in the US2
Although there has been remarkable success in the development of certain drugs for the treatment of viral-induced chronic liver disease the options for patients with cirrhosis remain limited
One patient’s journey
One patient’s journey, which represents the many lives that could be saved today and where Yaqrit is focused on developing solutions for patients at each stage of advanced liver disease
Meet David
David, a 52-year-old accountant, drinking 2 large glasses of wine per day is diagnosed with alcoholic cirrhosis during a routine health check.
No known liver disease previously.
Image not of actual patient.
Compensated cirrhosis
Admission
David is admitted to hospital with pneumonia. On admission he has a fever, raised inflammatory markers, jaundice and fluid accumulation in his abdomen.
Acute decompensation
Death
David develops progressive jaundice and goes into a coma requiring admission into intensive care.
He dies 5 days later with progressive liver, renal, circulatory, and cerebral failure.
Acute-on-chronic liver failure (ACLF)
Treating liver disease
Chronic liver disease is a complex, progressive multifactorial condition that evolves to cirrhosis, the leading cause of liver-related death globally3. The primary drivers of this progression are liver injury and inflammation. Yaqrit has harnessed its deep and new understanding of inflammation to identify novel therapeutic targets.
Compensated cirrhosis
Decompensated cirrhosis
Acute-on-chronic liver failure
Ntandja-Wandji, Line Carolle et al., (2020) Combined alcoholic and non-alcoholic steatohepatitis. JHEP Reports.
National Vital Statistics Reports, Deaths: Leading Causes for 2017.
Sepanlou S. et al. (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology.
D’Amico, Gennaro et al. (2006) Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. Journal of Hepatology.
Moreau R. et al. (2013). Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology.
Arroyo V., Moreau R., and Jalan R. (2020). Acute-on Chronic Liver Failure. The New England Journal of Medicine.
